

May 1, 2008

APA DSM-V Work Group Member

Name, Degree: **Ronald E. Dahl, M.D.**

Role(s) in Work Group: **Member, Disorders in Childhood and Adolescence Work Groups**

Institutional Affiliation(s): **University of Pittsburgh Medical Center**

City, State: **Pittsburgh, PA**

Biographical Sketch:

Ronald E. Dahl, M.D.

Staunton Professor of Psychiatry and Pediatrics, and Professor of Psychology

University of Pittsburgh

Pittsburgh, PA

Ronald E. Dahl, M.D. is the Staunton Professor of Psychiatry and Pediatrics, and Professor of Psychology at the University of Pittsburgh. He is a pediatrician with research interests in sleep/arousal and affect regulation and their relevance to the development of behavioral and emotional disorders in youth. His work focuses on early adolescence and pubertal development as a neurodevelopmental period with unique opportunities for early intervention. He co-directs a large program of research on child/adolescent anxiety and depression with more than twenty years of continuous funding from the NIMH, and he has received grants from NIAAA, NIDA, and NICHD focusing on questions of neurobehavioral development and adolescent health outcomes. His research is interdisciplinary and bridges from basic work in affective neuroscience and development and extends to clinical work focusing on early intervention for behavioral and emotional health problems. Dr. Dahl has published extensively on adolescent development, sleep disorders, and behavioral/emotional health in children and adolescents.

UNCOMPENSATED AFFILIATIONS WITH NON-PROFIT OR ADVOCACY ORGANIZATIONS THAT MAY HAVE A DIRECT OR INDIRECT INTEREST IN PSYCHIATRIC DIAGNOSIS, TREATMENT, OR THE DSM-V : **CALENDAR YEARS 2005, 2006, 2007, AND FOR 2008**, ACTIVITIES TO DATE AND COMMITMENTS FOR REMAINDER OF YEAR.

Non-Profit and Advocacy Organizations	Year(s)	Role
None		

The two tables below represent Dr. Dahl's disclosure of significant interests and affiliations for: (1) The full calendar years of 2005, 2006, and 2007; and (2) for 2008, interests and affiliations to date and commitments for remainder of the year.

Dr. Dahl has agreed that, from the time of approval through the publication of DSM-V, projected in 2012, (his/her) aggregate annual income derived from industry sources (excluding unrestricted research grants) will not exceed \$10,000 in any calendar year.

<p>KEY NUMBER:</p> <p>1. Consultation Fees (include scientific advisory boards)</p> <p>2. Full- or Part-time Employee</p> <p>3. Industry-related Grant-Research Support received or pending</p> <p>4. Honoraria (includes Speakers' Bureau)</p> <p>5. Stock or other financial options</p>	<p>6. Expert testimony</p> <p>7. Royalties (including right to share of revenue or profit from pharmaceutical, device or other development or product)</p> <p>8. Patents received or pending</p> <p>9. Officer, director/trustee, executive (specify)</p> <p>10. Other (specify)</p>
---	--

DISCLOSURE OF SIGNIFICANT INTERESTS FOR 2005, 2006, AND 2007

Commercial or Other Organization	Year(s)	Key #(s)
None		

DISCLOSURE OF SIGNIFICANT INTERESTS TO DATE FOR 2008 AND COMMITMENTS FOR REMAINDER OF YEAR

Commercial or Other Organization	Year(s)	Key #(s)
None		